Validation of Biomarker Proteins Using Reverse Capture Protein Microarrays

  • Catherine Jozwik
  • Ofer Eidelman
  • Joshua Starr
  • Harvey B. Pollard
  • Meera SrivastavaEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 1513)


Genomics has revolutionized large-scale and high-throughput sequencing and has led to the discovery of thousands of new proteins. Protein chip technology is emerging as a miniaturized and highly parallel platform that is suited to rapid, simultaneous screening of large numbers of proteins and the analysis of various protein-binding activities, enzyme substrate relationships, and posttranslational modifications. Specifically, reverse capture protein microarrays provide the most appropriate platform for identifying low-abundance, disease-specific biomarker proteins in a sea of high-abundance proteins from biological fluids such as blood, serum, plasma, saliva, urine, and cerebrospinal fluid as well as tissues and cells obtained by biopsy. Samples from hundreds of patients can be spotted in serial dilutions on many replicate glass slides. Each slide can then be probed with one specific antibody to the biomarker of interest. That antibody’s titer can then be determined quantitatively for each patient, allowing for the statistical assessment and validation of the diagnostic or prognostic utility of that particular antigen. As the technology matures and the availability of validated, platform-compatible antibodies increases, the platform will move further into the desirable realm of discovery science for detecting and quantitating low-abundance signaling proteins. In this chapter, we describe methods for the successful application of the reverse capture protein microarray platform for which we have made substantial contributions to the development and application of this method, particularly in the use of body fluids other than serum/plasma.

Key words

Proteomics Reverse capture protein microarray Antibodies Body fluids Biomarkers Bioinformatics 


  1. 1.
    Paweletz CP, Charboneau L, Bichsel VE et al (2001) Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20:1981–1989CrossRefPubMedGoogle Scholar
  2. 2.
    Gulmann C, Espina V, Petricoin E III et al (2005) Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. Clin Cancer Res 11:5847–5855CrossRefPubMedGoogle Scholar
  3. 3.
    Nishizuka S, Charboneau L, Young L et al (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100:14229–14234CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Sevecka M, MacBeath G (2006) State-based discovery: a multidimensional screen for small-molecule modulators of EGF signaling. Nat Methods 3:825–831CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Srivastava M, Eidelman O, Jozwik C et al (2006) Serum proteomic signature for cystic fibrosis using an antibody microarray platform. Mol Genet Metab 87:303–310CrossRefPubMedGoogle Scholar
  6. 6.
    Janzi M, Odling J, Pan-Hammarström Q et al (2005) Serum microarrays for large scale screening of protein levels. Mol Cell Proteomics 4:1942–1947CrossRefPubMedGoogle Scholar
  7. 7.
    Grubb RL, Calvert VS, Wulkuhle JD et al (2003) Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics 3:2142–2146CrossRefPubMedGoogle Scholar
  8. 8.
    Sheehan KM, Calvert VS, Kay EW et al (2005) Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics 4:346–355CrossRefPubMedGoogle Scholar
  9. 9.
    Wulfkuhle JD, Aquino JA, Calvert VS et al (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3:2085–2090CrossRefPubMedGoogle Scholar
  10. 10.
    Tibes R, Qiu Y, Lu Y et al (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5:2512–2521CrossRefPubMedGoogle Scholar
  11. 11.
    Jiang R, Mircean C, Shmulevich I et al (2006) Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. Proteomics 6:2964–2971CrossRefPubMedGoogle Scholar
  12. 12.
    Srivastava M, Eidelman O, Zhang J et al (2004) Digitoxin mimics CFTR-gene therapy, and suppresses hypersecretion of proinflammatory interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells. Proc Natl Acad Sci USA 101:7693–7698CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Srivastava M, Eidelman O, Torosyan Y et al (2011) Elevated expression levels of ANXA11, integrins β3 and α3, and TNFα contribute to a candidate proteomic signature in urine for kidney allograft rejection. Proteomics Clin Appl 5:311–321CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Srivastava M, Torosyan Y, Eidelman O et al (2015) Reduced PARP1 as a serum biomarker for graft rejection in kidney transplantation. J Proteomics Bioinform 8:2–6Google Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • Catherine Jozwik
    • 1
  • Ofer Eidelman
    • 1
  • Joshua Starr
    • 1
  • Harvey B. Pollard
    • 1
  • Meera Srivastava
    • 1
    Email author
  1. 1.Department of Anatomy, Physiology and Genetics, Institute for Molecular Medicine, Center for Medical ProteomicsUniformed Services University School of MedicineBethesdaUSA

Personalised recommendations